Risperdal

  • Risperdal

Janssen–Cilag, a subsidiary of Johnson & Johnson, launched an authorized version of Risperidone, an anti-psychotic drug, under the brand name Risperdal in the US in 2008, which had earlier received an FDA approval in 1993 for treating schizophrenia in adults.

Due to its antiadrenergic, antiserotonergic and anti-histaminergic properties and being a dopamine antagonist, it is used in the treatment of bipolar disorder and schizophrenia in adults and adolescents. It is also used to treat irritability in children aged 5-to-16 years on the autism spectrum.

Serious Alleged Injuries may include:

  • agitation
  • akathisia
  • anxiety
  • dizziness
  • constipation
  • drowsiness
  • vomiting
  • tachycardia
  • skin rash
  • xeroderma

FDA SAFETY WARNINGS:

April 2005: After receiving data that patients with dementia-related psychosis treated with atypical (second generation) antipsychotic medications are at an increased risk of death compared to placebo, the Food and Drug Administration (FDA) requested that the package insert for Risperdal to include a black box warning describing this risk and noting that this drug is not approved for this indication, giving September 2006 as the deadline to update.

 

Lawsuit Allegations:

At least 13,000 product liability claims involving Risperdal have been filed in courts across the US alleging that Johnson & Johnson was aware that the medication could cause gynecomastia but concealed that information to the public.

In February 2015, the first Risperdal trial went before the Philadelphia jury, resulting in a $2.5 million damage award for a 20-year-old man who suffered gynecomastia, breast growth, as a Risperdal side effect after using the medication for treatment of autism when he was 8 years old. Evidence presented at trial suggested that Johnson & Johnson's Risperdal (Janssen) unit knew about the link between Risperdal and gynecomastia as early as 2001, yet failed to warn consumers and the medical community. The same year, $1.75 million was awarded to another plaintiff.

In July 2016, $ 70 million was awarded to the plaintiff in a Philadelphia Risperdal litigation. In January 2017, as the company entered into a pre-trial settlement days before another Philadelphia trial.

There are over 2,000 cases pending in the Complex Litigation Center of the Philadelphia Court of Common Pleas, and another 300 cases pending in Los Angeles Superior Court. Most of the current litigation is pending in the Los Angeles Superior Court and the Philadelphia Court of Common Pleas in Pennsylvania

Evidences:

  • Risperdal usage by a Male in adolescence during 2006 to 2010
  • Hyperprolactinemia
  • Weight gain
  • Treatment or surgery for Gynecomastia

Medical Record Review and claim validation of Risperdal case should take approximately 3 hours in most instances; however, this approximation may vary in cases based on the volume of records.

Accreditations

HIPAA

Neural IT has successfully implemented HIPAA for securing Health records....

ISO 27001 Certification

Neural IT has successfully passed the ISMS re-certification audit and is now ISO 27001:2013 certi...

NSIC - CRISIL

NSIC-CRISIL has assigned a "SE 2A" rating to Neural IT, indicating a company with High Performanc...

Associations

CAALA

CAALA - "Neural IT is proud to be associated with CAALA (Consumer Attorneys Association of Los An...

CAOC

CAOC - "Neural IT is proud to be associated with CAOC (Consumer Attorneys of California) as a Ven...

NYSTLA

NYSTLA - "Neural IT is proud to be associated with NYSTLA (New York State Trial Lawyers Associati...

News & Events

‘Rewards & Recognition Program’ Celebrations
‘Rewards & Recognition Program’ Celebrations!
Hurricane Relief Fund
We donated to Hurricane Relief Fund and got a signed ball from Kareem Abdul-Jabbar, the greatest
AAJ Annual Convention 2017
Neural IT sponsored TRT meeting was one of the active participants of AAJ Annual Convention 2017.

Latest Tweets